UY29473A1 - Combinacion para terapia en hiperplasia benigna de prostata - Google Patents
Combinacion para terapia en hiperplasia benigna de prostataInfo
- Publication number
- UY29473A1 UY29473A1 UY29473A UY29473A UY29473A1 UY 29473 A1 UY29473 A1 UY 29473A1 UY 29473 A UY29473 A UY 29473A UY 29473 A UY29473 A UY 29473A UY 29473 A1 UY29473 A1 UY 29473A1
- Authority
- UY
- Uruguay
- Prior art keywords
- hyperplasia
- benigna
- prostata
- therapy
- combination
- Prior art date
Links
- 206010020718 hyperplasia Diseases 0.000 title 1
- 238000002560 therapeutic procedure Methods 0.000 title 1
- ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 abstract 2
- 229940099471 Phosphodiesterase inhibitor Drugs 0.000 abstract 2
- 238000013270 controlled release Methods 0.000 abstract 2
- 238000009472 formulation Methods 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- BNRNXUUZRGQAQC-UHFFFAOYSA-N sildenafil Chemical compound CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 BNRNXUUZRGQAQC-UHFFFAOYSA-N 0.000 abstract 2
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 abstract 1
- 208000004403 Prostatic Hyperplasia Diseases 0.000 abstract 1
- 229940123934 Reductase inhibitor Drugs 0.000 abstract 1
- DRHKJLXJIQTDTD-OAHLLOKOSA-N Tamsulosine Chemical compound CCOC1=CC=CC=C1OCCN[C@H](C)CC1=CC=C(OC)C(S(N)(=O)=O)=C1 DRHKJLXJIQTDTD-OAHLLOKOSA-N 0.000 abstract 1
- SECKRCOLJRRGGV-UHFFFAOYSA-N Vardenafil Chemical compound CCCC1=NC(C)=C(C(N=2)=O)N1NC=2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(CC)CC1 SECKRCOLJRRGGV-UHFFFAOYSA-N 0.000 abstract 1
- 239000000674 adrenergic antagonist Substances 0.000 abstract 1
- 229960004607 alfuzosin Drugs 0.000 abstract 1
- WNMJYKCGWZFFKR-UHFFFAOYSA-N alfuzosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(C)CCCNC(=O)C1CCCO1 WNMJYKCGWZFFKR-UHFFFAOYSA-N 0.000 abstract 1
- RUZYUOTYCVRMRZ-UHFFFAOYSA-N doxazosin Chemical compound C1OC2=CC=CC=C2OC1C(=O)N(CC1)CCN1C1=NC(N)=C(C=C(C(OC)=C2)OC)C2=N1 RUZYUOTYCVRMRZ-UHFFFAOYSA-N 0.000 abstract 1
- 229960001389 doxazosin Drugs 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 229960003310 sildenafil Drugs 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
- 229960000835 tadalafil Drugs 0.000 abstract 1
- IEHKWSGCTWLXFU-IIBYNOLFSA-N tadalafil Chemical compound C1=C2OCOC2=CC([C@@H]2C3=C([C]4C=CC=CC4=N3)C[C@H]3N2C(=O)CN(C3=O)C)=C1 IEHKWSGCTWLXFU-IIBYNOLFSA-N 0.000 abstract 1
- 229960002613 tamsulosin Drugs 0.000 abstract 1
- 229960001693 terazosin Drugs 0.000 abstract 1
- VCKUSRYTPJJLNI-UHFFFAOYSA-N terazosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1CCCO1 VCKUSRYTPJJLNI-UHFFFAOYSA-N 0.000 abstract 1
- 229960002381 vardenafil Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102005016981A DE102005016981A1 (de) | 2005-04-13 | 2005-04-13 | Kombination zur Therapie bei benigner Prostatahyperplasie |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UY29473A1 true UY29473A1 (es) | 2006-11-30 |
Family
ID=36608700
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UY29473A UY29473A1 (es) | 2005-04-13 | 2006-04-12 | Combinacion para terapia en hiperplasia benigna de prostata |
Country Status (22)
| Country | Link |
|---|---|
| EP (1) | EP1888075A1 (de) |
| JP (1) | JP2008535877A (de) |
| KR (1) | KR20080007252A (de) |
| CN (1) | CN101193638A (de) |
| AR (1) | AR053575A1 (de) |
| AU (1) | AU2006233567A1 (de) |
| BR (1) | BRPI0610634A2 (de) |
| CA (1) | CA2605224A1 (de) |
| CR (1) | CR9427A (de) |
| DE (1) | DE102005016981A1 (de) |
| DO (1) | DOP2006000074A (de) |
| GT (1) | GT200600145A (de) |
| IL (1) | IL186604A0 (de) |
| MA (1) | MA29683B1 (de) |
| MX (1) | MX2007012567A (de) |
| PE (1) | PE20061338A1 (de) |
| RU (1) | RU2007141518A (de) |
| SV (1) | SV2008002477A (de) |
| TN (1) | TNSN07385A1 (de) |
| TW (1) | TW200716122A (de) |
| UY (1) | UY29473A1 (de) |
| WO (1) | WO2006108519A1 (de) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6143746A (en) * | 1994-01-21 | 2000-11-07 | Icos Corporation | Tetracyclic cyclic GMP-specific phosphodiesterase inhibitors, process of preparation and use |
| US20070093493A1 (en) * | 2005-10-12 | 2007-04-26 | Lilly Icos Llc | Treatment of benign prostatic hypertrophy and lower urinary tract symptoms |
| JP2009520806A (ja) * | 2005-12-21 | 2009-05-28 | ファイザー・プロダクツ・インク | ＰＤＥ−５阻害薬と５−α還元酵素阻害薬の医薬組合せ |
| MX2008016569A (es) * | 2006-07-07 | 2009-01-30 | Teva Pharma | Composiciones solidas que contienen tadalafil y al menos un portador. |
| DE102007028869A1 (de) | 2007-06-22 | 2008-12-24 | Ratiopharm Gmbh | Verfahren zur Herstellung eines Arzneimittels enthaltend Tadalafil |
| AU2008334933B2 (en) | 2007-12-13 | 2016-01-21 | Vanda Pharmaceuticals Inc. | Method and composition for treating a serotonin receptor-mediated condition |
| WO2009076663A1 (en) | 2007-12-13 | 2009-06-18 | Vanda Pharmaceuticals Inc. | Method and composition for treating an alpha adrenoceptor-mediated condition |
| US8885621B2 (en) | 2010-04-26 | 2014-11-11 | Intel Corporation | Method, apparatus and system for switching traffic streams among multiple bands |
| WO2013123965A1 (en) * | 2012-02-20 | 2013-08-29 | Synthon Bv | A fixed dose pharmaceutical formulation |
| CN102727456B (zh) * | 2012-07-03 | 2016-06-22 | 北京科信必成医药科技发展有限公司 | 药物口腔崩解片及其制备方法 |
| KR102246657B1 (ko) * | 2013-06-28 | 2021-04-30 | 한미약품 주식회사 | 타다라필 및 탐수로신을 함유하는 약학적 캡슐 복합 제제 |
| AU2014293141A1 (en) | 2013-07-23 | 2016-02-18 | Serenity Pharmaceuticals Llc | Methods and compositions comprising desmopressin in combination with a beta-3 adrenergic receptor agonist |
| KR20150056443A (ko) * | 2013-11-15 | 2015-05-26 | 한미약품 주식회사 | 타다라필 및 암로디핀을 포함하는 복합제제 |
| WO2016003180A1 (ko) * | 2014-06-30 | 2016-01-07 | 한미약품 주식회사 | 5-α-환원효소 억제제-함유 필름 코팅층을 포함하는 복합제제 및 그 제조방법 |
| BR112016030731A2 (pt) * | 2014-06-30 | 2017-08-22 | Hanmi Pharm Ind Co Ltd | Preparação de compósito, e, método de preparação de uma preparação de compósito |
| CN106659690B (zh) * | 2014-06-30 | 2020-08-18 | 韩美药品株式会社 | 包括含有活性成分的膜包衣层的复合制剂 |
| CN106999538A (zh) * | 2014-11-20 | 2017-08-01 | 阿勒根公司 | 包含去氨加压素与α‑肾上腺素能受体拮抗剂组合的方法和组合物 |
| EA201891891A1 (ru) * | 2016-03-31 | 2019-04-30 | Ханми Фарм. Ко., Лтд. | Комбинированный препарат в виде капсулы, содержащий тадалафил и тамсулозин и обладающий улучшенной стабильностью и скоростью растворения |
| KR101835506B1 (ko) * | 2016-10-25 | 2018-03-07 | 주식회사 에스텍파마 | 두타스테리드와 타다라필을 함유하는 속효성 복합정제 |
| CN108066347B (zh) * | 2016-11-16 | 2021-02-02 | 深圳万和制药有限公司 | 包含坦索罗辛和度他雄胺的口腔崩解片药物组合物 |
| KR101879133B1 (ko) * | 2017-07-11 | 2018-07-17 | (주)동구바이오제약 | 비뇨기 질환 예방 또는 치료용 제제 및 이의 제조방법 |
| TR201715231A2 (tr) * | 2017-10-09 | 2019-04-22 | Montero Gida Sanayi Ve Ticaret Anonim Sirketi | Dapokseti̇n ve fosfodi̇esteraz ti̇p-5 i̇nhi̇bi̇törü i̇çeren farmasöti̇k kombi̇nasyon |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050042177A1 (en) * | 2003-07-23 | 2005-02-24 | Elan Pharma International Ltd. | Novel compositions of sildenafil free base |
-
2005
- 2005-04-13 DE DE102005016981A patent/DE102005016981A1/de not_active Withdrawn
-
2006
- 2006-03-29 DO DO2006000074A patent/DOP2006000074A/es unknown
- 2006-03-31 AU AU2006233567A patent/AU2006233567A1/en not_active Abandoned
- 2006-03-31 WO PCT/EP2006/002941 patent/WO2006108519A1/de not_active Ceased
- 2006-03-31 KR KR1020077026260A patent/KR20080007252A/ko not_active Withdrawn
- 2006-03-31 EP EP06723901A patent/EP1888075A1/de not_active Withdrawn
- 2006-03-31 RU RU2007141518/15A patent/RU2007141518A/ru unknown
- 2006-03-31 MX MX2007012567A patent/MX2007012567A/es not_active Application Discontinuation
- 2006-03-31 CA CA002605224A patent/CA2605224A1/en not_active Abandoned
- 2006-03-31 BR BRPI0610634-0A patent/BRPI0610634A2/pt not_active Application Discontinuation
- 2006-03-31 JP JP2008505765A patent/JP2008535877A/ja active Pending
- 2006-03-31 CN CNA2006800207814A patent/CN101193638A/zh active Pending
- 2006-04-07 SV SV2006002477A patent/SV2008002477A/es not_active Application Discontinuation
- 2006-04-10 GT GT200600145A patent/GT200600145A/es unknown
- 2006-04-11 AR ARP060101410A patent/AR053575A1/es unknown
- 2006-04-11 PE PE2006000383A patent/PE20061338A1/es not_active Application Discontinuation
- 2006-04-12 UY UY29473A patent/UY29473A1/es not_active Application Discontinuation
- 2006-04-12 TW TW095112920A patent/TW200716122A/zh unknown
-
2007
- 2007-10-09 CR CR9427A patent/CR9427A/es not_active Application Discontinuation
- 2007-10-11 TN TNP2007000385A patent/TNSN07385A1/en unknown
- 2007-10-11 IL IL186604A patent/IL186604A0/en unknown
- 2007-10-29 MA MA30335A patent/MA29683B1/fr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP1888075A1 (de) | 2008-02-20 |
| DE102005016981A1 (de) | 2006-10-19 |
| TNSN07385A1 (en) | 2009-03-17 |
| IL186604A0 (en) | 2008-01-20 |
| CA2605224A1 (en) | 2006-10-19 |
| TW200716122A (en) | 2007-05-01 |
| MX2007012567A (es) | 2007-12-10 |
| SV2008002477A (es) | 2008-02-08 |
| MA29683B1 (fr) | 2008-08-01 |
| AU2006233567A1 (en) | 2006-10-19 |
| JP2008535877A (ja) | 2008-09-04 |
| CR9427A (es) | 2007-12-17 |
| GT200600145A (es) | 2007-04-10 |
| DOP2006000074A (es) | 2006-10-15 |
| RU2007141518A (ru) | 2009-05-20 |
| CN101193638A (zh) | 2008-06-04 |
| PE20061338A1 (es) | 2007-01-28 |
| BRPI0610634A2 (pt) | 2010-07-13 |
| AR053575A1 (es) | 2007-05-09 |
| KR20080007252A (ko) | 2008-01-17 |
| WO2006108519A1 (de) | 2006-10-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY29473A1 (es) | Combinacion para terapia en hiperplasia benigna de prostata | |
| MX372673B (es) | Un inhibidor de btk para usarse en el tratamiento de penfigo y sales y formas sólidas del mismo. | |
| MX2021004639A (es) | Combinaciones de inhibidores de desmetilasa-1 especifica de lisina (lsd1) para uso en el tratamiento de tumores solidos. | |
| CR20190350A (es) | INHIBIDORES DE TGFß1 ISOFORMA-ESPECÍFICOS CONTEXTO-PERMISIVOS Y USO DE LOS MISMOS | |
| CY1116878T1 (el) | sGC ΔΙΕΓΕΡΤΕΣ Ή sGC ΕΝΕΡΓΟΠΟΙΗΤΕΣ ΜΟΝΟΙ ΚΑΙ ΣΕ ΣΥΝΔΥΑΣΜΟ ME PDE5 ΑΝΑΣΤΟΛΕΙΣ ΓΙΑ ΤΗΝ ΘΕΡΑΠΕΥΤΙΚΗ ΑΓΩΓΗ ΤΗΣ ΚΥΣΤΙΚΗΣ ΙΝΩΣΗΣ | |
| NO20070866L (no) | Antivirale forbindelser. | |
| MX2017011270A (es) | Composiciones farmaceuticas de un inhibidor de tirosina cinasa de bruton. | |
| EA201490194A1 (ru) | Комбинированная терапия, включающая ингибитор cdk4/6 и ингибитор pi3k для применения в лечении рака | |
| AR048819A1 (es) | Metodos sinergicos y composiciones para el tratamiento del cancer | |
| BR112015021995A2 (pt) | combinações de inibidores de tirosina quinase de bruton e inibidores de cyp3a4 | |
| WO2015193740A3 (en) | Therapeutic combinations of a btk inhibitor, a pi3k inhibitor and/or a jak-2 inhibitor | |
| GT200900182A (es) | Inhibidores de la poli (adp-ribosa) polimerasa | |
| CL2013002063A1 (es) | Compuestos derivados de pirrolo(piridina, pirimidina o pirazina), inhibidores de serina/trionina cinasa; composicion farmaceutica que los comprende; y su uso en el tratamiento del cancer, infecciones inflamaciones y enfermedades autoinmune. | |
| CR11100A (es) | Uso de inhibidores de piridopirimidinona de p13k-alfa en el tratamiento del cancer | |
| CL2007001996A1 (es) | Compuestos derivados de heteroarilos nitrogenados sustituidos con fenilo, inhibidores de la produccion de citoquinas; composicion farmaceutica que los comprende; y sus usos en el tratamiento del cancer, infecciones, enfermedades inflamatorias y autoinmunes. | |
| CL2008001364A1 (es) | Uso de compuestos derivados de imidazol(1,2-b) piridazina y pirazolo(1,5-a) pirimidina inhibidores de tirosina quinasa pi-para tratar tumor benigno o maligno, entre otros; compuestos dereivados de imidazol(1,2-b)piridazina y pirazolo(1,5-a)pirimidina; composiciones farmaceuticas; y metodo de preparacion de compuestos. | |
| EA201200550A1 (ru) | Фармацевтические композиции, включающие bi-1356 и метформин | |
| AR091876A1 (es) | Combinaciones farmaceuticas para el tratamiento de enfermedades proliferativas | |
| PE20070723A1 (es) | Imidazopirazinas como inhibidores de quinasas dependientes de ciclina | |
| EA201890957A1 (ru) | Комбинированная терапия для лечения злокачественных опухолей | |
| NO20081973L (no) | PDE inhibitorer og kombinasjoner derav i behandlingen av urologiske lidelser | |
| SV2008002855A (es) | Milnacipran para el tratamiento a largo plazo del sindrome de fibromialgia | |
| EP4233840A3 (de) | Kombinationen aus linagliptin und metformin | |
| MX2021014175A (es) | Tratamiento de trastornos de perdida de cabello con inhibidores de cinasas asociadas a janus (jak) deuterados. | |
| ECSP045021A (es) | Terapia de combinacion para el tratamiento del cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 109 | Application deemed to be withdrawn |
Effective date: 20160810 |